# **Special Issue**

# HIV Elimination as the Goal by 2030

## Message from the Guest Editor

Our society constantly faces important public health crises, potentially affecting millions of people and, often, many lives lost. The HIV/AIDS epidemic is one of these crises, mobilizing the global community over the last forty years. Over that period, huge progress has been made to reduce the burden of the disease by improving the diagnosis as well as the access to more potent antiretroviral drugs and engaging in better monitoring of this life-long treatment. Building on these successes, UNAIDS has launched ambitious initiatives and targets as the 90-90-90 targets, and designed transformative actions to end the global AIDS epidemic by 2030. Although the impressive scale-up of antiretroviral treatments over the past 20 years, especially in the most affected regions of the world, makes such a goal achievable, there are still important challenges. In this Special Issue, I welcome your recent research and results that present linkages with this ambitious goal of HIV/AIDS elimination by the next decade. I am convinced that this Special Issue will help inform the global community about the ongoing successes and the remaining challenges towards achieving this goal.

### **Guest Editor**

Dr. Avelin F. Aghokeng Institut de Recherche pour le Développement (IRD), Marseille, French

## Deadline for manuscript submissions

closed (20 July 2023)



## **Viruses**

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/121095

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





# Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

#### **Editor-in-Chief**

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

#### **Author Benefits**

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

## **Journal Rank:**

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

## **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

